BlackRock
RLAY icon

BlackRock’s Relay Therapeutics RLAY Stock Holding History

BlackRock’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286M Buy
15,288,202
+2,312,903
+18% +$33.6M ﹤0.01% 1574
2026
Q1 		$129M Sell
12,975,299
-253,203
-2% -$2.27M ﹤0.01% 1952
2025
Q4 		$112M Sell
13,228,502
-530,880
-4% -$3.79M ﹤0.01% 2039
2025
Q3 		$71.8M Sell
13,759,382
-195,104
-1% -$744K ﹤0.01% 2286
2025
Q2 		$48.3M Sell
13,954,486
-524,312
-4% -$1.56M ﹤0.01% 2467
2025
Q1 		$37.9M Sell
14,478,798
-195,464
-1% -$766K ﹤0.01% 2526
2024
Q4 		$60.5M Buy
14,674,262
+2,932,115
+25% +$16M ﹤0.01% 2343
2024
Q3 		$83.1M Buy
11,742,147
+1,199,480
+11% +$8.96M ﹤0.01% 2188
2024
Q2 		$68.7M Buy
10,542,667
+746,457
+8% +$5.1M ﹤0.01% 2244
2024
Q1 		$81.3M Buy
9,796,210
+222,787
+2% +$2.17M ﹤0.01% 2172
2023
Q4 		$105M Buy
9,573,423
+1,243,656
+15% +$10.5M ﹤0.01% 2040
2023
Q3 		$70.1M Sell
8,329,767
-37,961
-0.5% -$408K ﹤0.01% 2195
2023
Q2 		$105M Buy
8,367,728
+432,038
+5% +$5.37M ﹤0.01% 2014
2023
Q1 		$131M Sell
7,935,690
-62,295
-0.8% -$1.12M ﹤0.01% 1851
2022
Q4 		$119M Buy
7,997,985
+1,240,348
+18% +$23.7M ﹤0.01% 1880
2022
Q3 		$151M Buy
6,757,637
+180,459
+3% +$3.96M 0.01% 1684
2022
Q2 		$110M Buy
6,577,178
+602,995
+10% +$12.9M ﹤0.01% 1945
2022
Q1 		$179M Sell
5,974,183
-19,430
-0.3% -$471K ﹤0.01% 1749
2021
Q4 		$184M Buy
5,993,613
+641,001
+12% +$20.3M ﹤0.01% 1793
2021
Q3 		$169M Buy
5,352,612
+812,282
+18% +$27.3M ﹤0.01% 1847
2021
Q2 		$166M Buy
4,540,330
+741,600
+20% +$24.4M ﹤0.01% 1913
2021
Q1 		$131M Buy
3,798,730
+641,756
+20% +$27.9M ﹤0.01% 2019
2020
Q4 		$131M Buy
3,156,974
+1,091,529
+53% +$49.3M ﹤0.01% 1907
2020
Q3 		$88M Buy
+2,065,445
New +$78.8M ﹤0.01% 1958

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock's RLAY Position: Q2 2026 in Review

BlackRock increased its Relay Therapeutics (RLAY) stake by 18% in Q2 2026, buying an estimated $33.6M and bringing the position to 15,288,202 shares worth $286M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

BlackRock first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • BlackRock held 15,288,202 shares of Relay Therapeutics worth $286M as of Q2 2026.
  • BlackRock bought 2,312,903 Relay Therapeutics shares in Q2 2026, an estimated $33.6M.
  • Relay Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1574 holding.
  • BlackRock first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.